Literature DB >> 24084743

Pharmacological agents currently in clinical trials for disorders in neurogastroenterology.

Michael Camilleri.   

Abstract

Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients' symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24084743      PMCID: PMC3784550          DOI: 10.1172/JCI70837

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  99 in total

1.  Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias.

Authors:  Henry Buchwald; Kyle D Rudser; Stanley E Williams; Van N Michalek; James Vagasky; John E Connett
Journal:  Ann Surg       Date:  2010-06       Impact factor: 12.969

2.  Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry.

Authors:  Yu Kyung Cho; Myung-Gyu Choi; Eun Young Park; Chul Hyun Lim; Jin Su Kim; Jae Myung Park; In Seok Lee; Sang Woo Kim; Kyu Yong Choi
Journal:  Dig Dis Sci       Date:  2012-10-06       Impact factor: 3.199

3.  Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome.

Authors:  J Czimmer; G Süto; A Király; G Mózsik
Journal:  J Physiol Paris       Date:  2001 Jan-Dec

4.  Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.

Authors:  Ashok K Tuteja; John C Fang; Manal Al-Suqi; Gregory J Stoddard; Devon C Hale
Journal:  Scand J Gastroenterol       Date:  2012-07-12       Impact factor: 2.423

Review 5.  Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials.

Authors:  Ewan McNicol; David B Boyce; Roman Schumann; Daniel Carr
Journal:  Pain Med       Date:  2008-09       Impact factor: 3.750

6.  Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man.

Authors:  D Ang; H Nicolai; R Vos; K Mimidis; F Akyuz; S Kindt; P Vanden Berghe; D Sifrim; I Depoortere; T Peeters; J Tack
Journal:  Neurogastroenterol Motil       Date:  2008-01-30       Impact factor: 3.598

7.  A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.

Authors:  Winfried Meissner; Petra Leyendecker; Stefan Mueller-Lissner; Joachim Nadstawek; Michael Hopp; Christian Ruckes; Stefan Wirz; Wolfgang Fleischer; Karen Reimer
Journal:  Eur J Pain       Date:  2008-08-31       Impact factor: 3.931

8.  Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.

Authors:  S M Leventer; K Raudibaugh; C L Frissora; N Kassem; J C Keogh; J Phillips; A W Mangel
Journal:  Aliment Pharmacol Ther       Date:  2007-10-31       Impact factor: 8.171

9.  Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome.

Authors:  M Delvaux; A Beck; J Jacob; H Bouzamondo; F T Weber; J Frexinos
Journal:  Aliment Pharmacol Ther       Date:  2004-07-15       Impact factor: 8.171

10.  Differential effects of transient receptor vanilloid one (TRPV1) antagonists in acid-induced excitation of esophageal vagal afferent fibers of rats.

Authors:  S Peles; B K Medda; Zhihong Zhang; B Banerjee; A Lehmann; R Shaker; J N Sengupta
Journal:  Neuroscience       Date:  2009-03-24       Impact factor: 3.590

View more
  12 in total

Review 1.  Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea.

Authors:  Michael Camilleri
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-17       Impact factor: 11.382

Review 2.  Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias.

Authors:  J R Giudicessi; M J Ackerman; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-14       Impact factor: 3.598

Review 3.  Gastric emptying and glycaemia in health and diabetes mellitus.

Authors:  Liza K Phillips; Adam M Deane; Karen L Jones; Chris K Rayner; Michael Horowitz
Journal:  Nat Rev Endocrinol       Date:  2014-11-25       Impact factor: 43.330

Review 4.  Elobixibat and its potential role in chronic idiopathic constipation.

Authors:  Andres Acosta; Michael Camilleri
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

5.  Validating biomarkers of treatable mechanisms in irritable bowel syndrome.

Authors:  M Camilleri; A Shin; I Busciglio; P Carlson; A Acosta; A E Bharucha; D Burton; J Lamsam; A Lueke; L J Donato; A R Zinsmeister
Journal:  Neurogastroenterol Motil       Date:  2014-09-22       Impact factor: 3.598

Review 6.  Prokinetics in the Management of Functional Gastrointestinal Disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2017-09-08

Review 7.  Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms.

Authors:  Michael Camilleri
Journal:  J Physiol       Date:  2014-03-24       Impact factor: 5.182

8.  Prokinetics in the Management of Functional Gastrointestinal Disorders.

Authors:  Eamonn M M Quigley
Journal:  J Neurogastroenterol Motil       Date:  2015-07-30       Impact factor: 4.924

Review 9.  Adenosine A2B Receptors: An Optional Target for the Management of Irritable Bowel Syndrome with Diarrhea?

Authors:  Teita Asano; Mitsuko Takenaga
Journal:  J Clin Med       Date:  2017-11-03       Impact factor: 4.241

Review 10.  Recent Updates on the Treatment of Constipation.

Authors:  Han Seung Ryu; Suck Chei Choi
Journal:  Intest Res       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.